A combination of two cancer therapy drugs has extended the lifespan of mice by up to 30%, according to a new international study published in Nature Aging. The drug combination also appeared to reduce age-related inflammation, delay the onset of certain cancers, and influence genes linked to aging.
Familiar Medications, Novel Application
The study centers around rapamycin and trametinib, both already used clinically to treat specific cancers. Rapamycin has been under investigation for several years for its potential effects on longevity, with previous research conducted on yeast, worms, flies, and now, mammals. This research represents a significant step in understanding the potential for pharmacological interventions to impact the aging process and age-related diseases.
Led by researchers from University College London and the Max Planck Institute for Biology of Ageing, the study is the first to test the combined effects of these two drugs on aging mice.
The results showed a 15 to 20% increase in lifespan with rapamycin alone, a 5 to 10% increase with trametinib, and up to a 29% increase when the drugs were used in combination.
Targeting Core Aging Pathways
The drug combination works by impacting two distinct but crucial cellular signaling pathways involved in aging and chronic disease development:
-
Rapamycin inhibits the mTOR protein, which plays a role in cell growth, division, and programmed cell death. This pathway is also heavily involved in metabolic diseases, cancers, and cognitive decline.
-
Trametinib targets the RAS/Mek/Erk pathway, known for its role in cancer cell proliferation, as well as its connection to cellular renewal and inflammatory responses.
Researchers found that the drugs don’t simply have additive effects when combined; they trigger unique changes in gene expression, different from those observed when each drug is used individually. This suggests a synergistic effect that warrants further investigation.
Not a Fountain of Youth, But Promising
It’s important to note that results in mice don’t always translate to humans, and widespread use of these drugs as “anti-aging elixirs” is still a long way off. However, their existing FDA approval for other conditions is encouraging, as it could expedite testing in human clinical trials.
Linda Partridge, a lead author of the study, explained:
“We do not expect to see such dramatic results in humans as we have in mice, but our goal is to improve the quality of life during aging.”
A New Wave of Anti-Aging Treatments?
This study is part of a growing field of research focused on “geroprotectors”—molecules that can slow biological aging or prevent age-related diseases such as Alzheimer’s, certain cancers, and type 2 diabetes. The potential to proactively address the underlying causes of age-related decline is a major focus of modern medical research.
Trametinib and rapamycin may become leading candidates in this category. However, optimizing dosage is crucial; trametinib, for example, can cause weight loss and liver damage in mice, highlighting the need to balance benefits with potential side effects.
Living Longer, and Better
Behind this pursuit of longevity, scientists are primarily focused on improving quality of life. Extending lifespan is only meaningful if individuals can maintain independence, cognitive function, and quality health. The goal is to delay the onset of chronic diseases, rather than simply adding years to life.
This unexpected yet promising drug combination could represent a first step toward preventative medicine for aging. Further research will determine if these promises materialize, but one thing is certain: the science of aging is evolving rapidly.
